C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
09 Abril 2024 - 8:00AM
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage
biopharmaceutical company dedicated to advancing targeted protein
degradation science, today announced that C4T management will
participate in a fireside chat at the Stifel 2024 Targeted Oncology
Forum taking place virtually from April 16 – April 17, 2024.
Fireside Chat Details:Event: Stifel 2024
Targeted Oncology ForumDate/Time: Tuesday, April 16, 2024 from
10:30 am ET – 10:55 am ET
A live webcast will be available on the Investors section of the
company’s website at www.c4therapeutics.com. An archived replay of
the webcast will be available for approximately 30 days following
the live event.
About C4 TherapeuticsC4 Therapeutics (C4T)
(Nasdaq: CCCC) is a clinical-stage biopharmaceutical company
dedicated to delivering on the promise of targeted protein
degradation science to create a new generation of medicines that
transforms patients’ lives. C4T is progressing targeted oncology
programs through clinical studies and leveraging its TORPEDO®
platform to efficiently design and optimize small-molecule
medicines to address difficult-to-treat diseases. C4T’s degrader
medicines are designed to harness the body’s natural protein
recycling system to rapidly degrade disease-causing proteins,
offering the potential to overcome drug resistance, drug
undruggable targets and improve patient outcomes. For more
information, please visit www.c4therapeutics.com.
Contacts:Investors: Courtney SolbergSenior
Manager, Investor RelationsCSolberg@c4therapeutics.com
Media: Loraine Spreen Senior Director, Corporate Communications
& Patient Advocacy LSpreen@c4therapeutics.com
C4 Therapeutics (NASDAQ:CCCC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
C4 Therapeutics (NASDAQ:CCCC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024